docetaxel anhydrous has been researched along with cobaltous chloride in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (cobaltous chloride) | Trials (cobaltous chloride) | Recent Studies (post-2010) (cobaltous chloride) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 1,935 | 8 | 737 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alshaker, H; Arafat, T; Böhler, T; Cooper, C; Kawano, Y; Pchejetski, D; Wang, Q; Winkler, M | 1 |
1 other study(ies) available for docetaxel anhydrous and cobaltous chloride
| Article | Year |
|---|---|
Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cobalt; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice, Inbred BALB C; Mice, Nude; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; RNA Interference; Signal Transduction; Taxoids; Time Factors; TOR Serine-Threonine Kinases; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |